HVB MINI FUTURE BULL - ASTRAZENECA | Real-time BOERSE MUENCHEN 11:46:45 2024-06-03 EDT | ||
| 5.61 EUR | +2.94% |
|
| 1 month | +3.42% | ||
| 3 months | +75.81% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-06-03 | 5.61 | +2.94% |
| 24-05-31 | 5.45 | +3.61% |
| 24-05-30 | 5.26 | +2.53% |
| 24-05-29 | 5.13 | -1.91% |
| 24-05-28 | 5.23 | -5.94% |
Real-time BOERSE MUENCHEN
Last update June 03, 2024 at 11:46 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HR6XM2 |
| ISIN | DE000HR6XM21 |
| Date issued | 2021-04-19 |
| Strike | 7,570 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.72 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.99 € |
|---|---|
| Lowest since issue | 0.79 € |
| Spread | 0.03 € |
| Spread % | 0.53% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
155.1
USD
Average target price
172
USD
Spread / Average Target
+10.91%
- Stock Market
- Certificates
- Certificat
